Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2021-10-22
Product name
FARECLA G3 PRO SPRAY WAX
CAS No.
67-63-0
1.2.2. Uses advised against
This material should not be used for any other purpose than the identified uses without expert advice. Improper use may cause potential health, safety and environmental risks
supplier name
Farecla Products Limited
Manufacturer Name
Farecla Products Limited
Icons in SDS
Company Information
company name
Saint-Gobain Coating Solutions
e-mail address of the competent person responsible for the Safety Data Sheet
-ehs.coating-solutions@saint-gobain.com, technical@farecla.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H319
Hazard statements
Code
Statements
H319
Causes serious eye irritation
Section 2
CLP CLASSIFICATION
Serious eye damage/eye irritation, Category 2 H319 Full text of H- and EUH-statements: see section 16
Adverse physicochemical, human health and environmental effects
Causes serious eye irritation.
2.2 Label elements
Labelling according to Regulation (EC) No. 1272/2008 [CLP]
Hazard pictograms
GHS07
Signal word
Warning
Hazard statements
H319 - Causes serious eye irritation.
Precautionary statements
P102 - Keep out of reach of children. P264 - Wash hands, forearms and face thoroughly after handling. P280 - Wear protective gloves, protective clothing, eye protection, face protection. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337+P313 - If eye irritation persists: Get medical advice/attention. Nordic countries regulation Denmark Danish product registration number : PR-4355184 MAL code : 1-3
Other hazards which do not result in classification
None under normal conditions. This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605
